Achieve Life Sciences Inc (ACHV)
$5.02
Performance
- $4.96$5.12$5.02
1.2%
Downside
Day's Volatility :3.13%
Upside
1.95%
- $3.03$5.98$5.02
39.64%
Downside
52 Weeks Volatility :49.33%
Upside
16.05%
Returns
| Period | Achieve Life Sciences Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 9.83% | 0.0% |
6 Months | 15.37% | 0.0% |
1 Year | 26.38% | 0.0% |
3 Years | -39.4% | -21.4% |
Highlights
Market Capitalization | 172.4M |
Book Value | $1.23 |
Earnings Per Share (EPS) | -1.07 |
PEG Ratio | 0.0 |
Wall Street Target Price | 16.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -33.84% |
Return On Equity TTM | -105.95% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -25.1M |
Diluted Eps TTM | -1.07 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.04 |
EPS Estimate Next Year | -1.06 |
EPS Estimate Current Quarter | -0.23 |
EPS Estimate Next Quarter | -0.28 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 218.73%
Technicals Summary
Sell
Neutral
Buy
Achieve Life Sciences Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Achieve Life Sciences Inc | 17.25% | 15.37% | 26.38% | -39.4% | -84.76% |
 Regeneron Pharmaceuticals, Inc. | -11.53% | 7.92% | 21.76% | 83.48% | 256.87% |
 Novo Nordisk A/s | -12.73% | -9.68% | 25.05% | 134.03% | 343.37% |
 Alnylam Pharmaceuticals, Inc. | 5.86% | 71.74% | 59.21% | 32.07% | 248.13% |
 Vertex Pharmaceuticals Incorporated | -3.35% | 12.64% | 28.18% | 152.92% | 164.64% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Achieve Life Sciences Inc | NA | NA | 0.0 | -1.04 | -1.06 | -0.34 | NA | 1.23 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Achieve Life Sciences Inc | Buy | $172.4M | -84.76% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 256.87% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 343.37% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.4B | 248.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 164.64% | 32.84 | -4.74% |
Insights on Achieve Life Sciences Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 51.5% return, outperforming this stock by 26.9%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 32.1% return, outperforming this stock by 71.6%
Institutional Holdings
Franklin Resources Inc
17.62%Propel Bio Management LLC
7.14%BlackRock Inc
5.70%Vanguard Group Inc
4.38%Sofinnova Ventures
4.04%Nantahala Capital Management, LLC
3.81%
Company Information
achieve life sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.
Organization | Achieve Life Sciences Inc |
Employees | 22 |
CEO | Mr. Thomas B. King M.B.A. |
Industry | Health Technology |
Discover More
Generations Bancorp Ny Inc
$5.02
-0.2%
Innovator Us Equity Accelerated Etf - April
$5.02
-0.2%
First Trust Exchange-traded
$5.02
-0.2%
Udemy, Inc.
$5.02
-0.2%
Trubridge Inc
$5.02
-0.2%
Stone Ridge 2049 Inflation-protected Longevity Income Etf
$5.02
-0.2%
Farmers National Banc Corp
$5.02
-0.2%
Bbb Foods Inc.
$5.02
-0.2%
Spdr Ssga Us Eq Prem Inc Etf
$5.02
-0.2%